皓元醫藥(688131.SH):尚未與阿里醫療、螞蟻醫療、平安醫療合作
格隆匯7月16日丨皓元醫藥(688131.SH)在投資者互動平臺表示,公司目前尚未與阿里醫療、螞蟻醫療、平安醫療合作。公司積極擁抱前沿技術,深度融合AI技術,構建了包含MegaUni庫在內的多個兼具新穎性、多樣性、潛在成藥性的獨特化合物庫,依託生成式AI技術,縮短研發週期,助力新穎產品的設計以及新合成方法的開發,全面覆蓋生物醫藥領域的小分子化合物應用場景。今年4月底,公司與華東師範大學正式簽署合作協議,共同建立“AI藥物探索聯合實驗室”,依託校企雙方的科研優勢與產業資源,重點突破AI技術在藥物研發領域的創新應用,構築“AI+生物醫藥”創新高地,爲國內新藥研發及科研成果轉化注入強勁動力。 此外,公司致力於開展小核酸藥物、多肽藥物、ADC藥物等新型藥物的技術研發,打造小核酸藥物和多肽藥物研發技術平臺,以AI計算機輔助藥物設計技術爲手段,提高小核酸藥物和多肽藥物開發的服務能力。未來,公司將繼續積極探索生物醫藥與AI、材料等交叉學科的協同創新,通過高校及科研機構深度合作突破技術壁壘,創新賦能公司高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.